Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) announced that a macrophage CUD005 injection (“CUD005 injection”) independently developed by the company's shareholding company, Sichuan Kangdesai Medical Technology Co., Ltd. (“CUD005 injection”) has obtained implied approval for drug clinical trials and obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to carry out clinical trials to treat decompensated liver cirrhosis.

According to the announcement, CUD005 injection is based on the patient's autoimmune cells, which are differentiated into mature and stable individualized anti-fibrotic macrophages, which can degrade the extracellular matrix and reduce liver scarring by secreting various matrix metalloproteinases. Furthermore, CUD005 injection can release anti-inflammatory factors, thereby inhibiting the occurrence of inflammatory reactions, improving the microenvironment of liver inflammation, and slowing the development of the condition.